Impression Healthcare has made key leadership and board changes.


Impression Healthcare (ASX:IHL) has appointed an internationally recognised key opinion leader in cannabinoid medicines, Dr Sud Agarwal, as the company’s Chief Medical Officer and Non-Executive Director.


The appointment will add significant medical, scientific and cannabis-related expertise to the company’s senior management team, and will aid in Impression Healthcare’s current and future research, as well as its ongoing commercial programs.


The company has also formed a Medical Advisory Board which is to be headed by Dr Agarwal—who is a qualified anaesthetist, the former Medical Director of the Cann Group and current CEO and Managing Director of Cannvalate—which will oversee clinical trial programs, product commercialisation strategies and assist with furthering defendable intellectual property.


The CEO and Managing Director of Impression Healthcare, Joel Latham, said that the company is “delighted that Dr Agarwal has joined our team as an expert and early-mover in the medicinal cannabis field.”


“His appointment is game-changing to the rapid commercialisation of key proprietary drugs being developed by IHL. His experience and knowledge are second-to-none and will help to perfect our strategy in the cannabis field whilst also opening the Company to global opportunities in this rapidly advancing sector”.

– Managing Director and CEO of Impression Healthcare, Joel Latham


As part of his role on the company’s Medical Advisory Board, Agarwal will bring his extensive cannabis expertise to Impression’s current and upcoming clinical programs, targeting conditions such as sleep apnoea, concussion, gum disease and TMJ disorder.


According to senior management, Agarwal’s ability to leverage patient groups will also support the company’s strategy for brining Impression’s products to the commercial market.


Please read the full article here.